Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-AOS4
- Development stage
- Unknown
- Lead developer
- GlycosBio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
GB-AOS4 is a clinical-stage therapeutic candidate being developed by GlycosBio for the treatment of acne. It utilizes the company's proprietary Activated Oil System (AOS), a lipid-based technology platform that employs modified oils and fatty acids to achieve therapeutic effects. The AOS technology is designed to provide a biocompatible and 'clean' alternative to traditional dermatological treatments, potentially targeting the skin microbiome or inflammatory pathways associated with acne. GB-AOS4 is part of a broader pipeline of AOS-based products (including GB-AOS-1, GB-AOS-2, and GB-AOS3) aimed at various skin conditions and general skincare applications.
Beyond the preview
Go deeper on GB-AOS4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-AOS4.